Analysts expect that Opko Health, Inc. (NASDAQ:OPK) will post earnings of ($0.05) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at $0.00. Opko Health reported earnings of ($0.03) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 66.7%. The firm is scheduled to issue its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Opko Health will report full-year earnings of ($0.19) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.13). For the next fiscal year, analysts expect that the company will post earnings of ($0.03) per share, with EPS estimates ranging from ($0.15) to $0.10. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Opko Health.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $314.20 million during the quarter, compared to analyst estimates of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company’s quarterly revenue was down 12.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.02 earnings per share.

Several equities research analysts have recently commented on OPK shares. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 price target on shares of Opko Health in a research note on Friday, June 16th. Jefferies Group LLC restated a “hold” rating and set a $6.50 price target (down previously from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Barrington Research upped their price target on Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. Opko Health currently has a consensus rating of “Hold” and a consensus price target of $14.61.

In other news, Director Richard A. Lerner bought 10,000 shares of the stock in a transaction on Monday, June 5th. The shares were bought at an average price of $6.31 per share, with a total value of $63,100.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Phillip Md Et Al Frost bought 9,200 shares of the stock in a transaction on Friday, May 19th. The stock was purchased at an average cost of $6.60 per share, for a total transaction of $60,720.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $20,255,076.60. The disclosure for this purchase can be found here. Insiders have purchased 1,577,400 shares of company stock worth $10,023,527 in the last ninety days. 40.19% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Piedmont Investment Advisors LLC raised its stake in Opko Health by 43.4% in the second quarter. Piedmont Investment Advisors LLC now owns 230,643 shares of the biotechnology company’s stock valued at $1,518,000 after buying an additional 69,818 shares during the period. Psagot Investment House Ltd. raised its stake in Opko Health by 20.0% in the second quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 3,806 shares during the period. The Manufacturers Life Insurance Company raised its stake in Opko Health by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,657 shares during the period. State Street Corp raised its stake in Opko Health by 3.9% in the second quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock valued at $74,671,000 after buying an additional 422,203 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. purchased a new stake in Opko Health during the second quarter valued at $1,335,000. 22.94% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “-$0.05 Earnings Per Share Expected for Opko Health, Inc. (OPK) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/16/0-05-earnings-per-share-expected-for-opko-health-inc-opk-this-quarter.html.

Opko Health (NASDAQ OPK) traded down 0.49% during mid-day trading on Wednesday, hitting $6.06. 4,223,188 shares of the company’s stock traded hands. The stock’s market cap is $3.39 billion. Opko Health has a one year low of $5.99 and a one year high of $12.15. The firm’s 50-day moving average price is $6.33 and its 200-day moving average price is $7.22.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.